NX-210c is under clinical development by Axoltis Pharma and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NX-210c’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NX-210c overview
NX-210c is under development for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis (RRMS), unspecified indication. The drug candidate is NX-210 analog which is a synthetic peptide derived from subcommissural organ-spondin. It is administered through intravenous route.
It was also under development for spinal cord injury.
Axoltis Pharma overview
Axoltis Pharma is a biopharmaceutical company that develop therapies for patients with traumatic and severe neurological disorders. The company’s pipeline product include NX210 which is a drug with a disease-modifying effect to target a broad range of central nervous system (CNS) diseases. It also treats parkinson disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis and other indications where blood brain barrier is impaired. The company operates in Clermont-Ferrand and and Lyon, France. Axoltis Pharma is headquartered in Clermont-Ferrand, France.
For a complete picture of NX-210c’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
